Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
628 Leser
Artikel bewerten:
(2)

Ludovic Luzza appointed General Manager of Generix Group North America


Press release
November 30th 2021

Generix Group, a global provider of collaborative SaaS Software solutions for the Supply Chain, industrial, and retail ecosystems, announced today the appointment of Ludovic Luzza as General Manager of Generix Group North America. Previously group's Chief Financial Officer, Ludovic's mission will now be to accelerate the development of Generix Group's North American entity.

As early as 2016, with the acquisition of Sologlobe, Generix Group confirmed its desire to develop on the North American market and thus strengthen its position as an international supply chain player. This ambition is set to accelerate significantly, as reflected in the recently announced strategic plan for 2025 entitled "Boost together 2025". It is in this context that the appointment of Ludovic Luzza, previously Chief Financial Officer of the Group, comes into effect.

Ludovic Luzza's objective will be to accelerate the development of the North American entity thanks to his perfect knowledge of the company's ecosystem, which will enable the implementation of even more synergies between the headquarters and the subsidiary. This will be based on the triptych that represents Generix Group's strength:

  • Human capital, thanks to a team of expert employees that will be enhanced with new recruitments of multidisciplinary profiles,
  • Customer capital by relying on a valuable installed base of North American customers who will benefit in the coming months from all Generix Group solutions beyond the SOLOCHAIN WMS (notably Supply Chain Execution, EDI and VMI solutions),
  • The partner ecosystem Generix Group already has in North America (notably with integrator partners such as LIDD). These partnerships are clearly identified as growth drivers for the subsidiary.

"I am very pleased to take over the management of Generix Group's North American subsidiary. The dynamics of this market and its strong strategic importance for the Group's development make it a key geography. It has a rich human capital and a solid installed base of customers. I am committed to placing customer satisfaction at the heart of the North American subsidiary's development strategy and - in particular thanks to our partners - to extending our presence to new customers in our priority sectors (Industry, FMCG, Retail and e-commerce and 3PL)" commented Ludovic Luzza.

Ludovic Luzza holds a degree in Accounting and Finance and started his career in 2002 in the retail industry. He was then Audit Manager for Mazars in Lille from 2004 to 2009. Ludovic joined Generix Group in 2009, from which date he has led an in-depth transformation of the financial and administrative organization, in order to support the daily performance of the business units and Generix Group's exposure on its markets. He was also at the forefront of the Group's acquisition projects, notably Sologlobe in 2016 in North America, until his appointment as head of the subsidiary today

About Generix Group
Generix Group is an expert in the Collaborative Supply Chain with presence in 60 countries thanks to its subsidiaries and network of partners. More than 6,000 companies around the world use its SaaS solutions. The group's 800 employees provide daily assistance to clients such as Carrefour, Danone, FM Logistic, Fnac-Darty, Essilor, Ferrero and Geodis in the digital transformation of their Supply Chains. Its collaborative platform, Generix Supply Chain Hub, helps companies keep their promises to their customers. It connects companies to all their partners so together they can operate physical flows, digitize information flows, and collaboratively manage processes in real time. Generix Supply Chain Hub is intended for all actors in the supply chain: manufacturers, logistic service providers

Press contact Marie Cannamela - generixgroup@angie.fr- 06.42.51.20.01

Attachment

  • EN_PR_Nomination_Ludovic Luzza (https://ml-eu.globenewswire.com/Resource/Download/c24bc4ba-ce36-45c8-a453-421e45f6fa1d)

© 2021 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.